CN115175676A - 淫羊藿苷元的医药用途 - Google Patents

淫羊藿苷元的医药用途 Download PDF

Info

Publication number
CN115175676A
CN115175676A CN202180019441.4A CN202180019441A CN115175676A CN 115175676 A CN115175676 A CN 115175676A CN 202180019441 A CN202180019441 A CN 202180019441A CN 115175676 A CN115175676 A CN 115175676A
Authority
CN
China
Prior art keywords
drug
group
bleeding
thrombolytic
caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180019441.4A
Other languages
English (en)
Inventor
张贵民
姚景春
孙成宏
李斌
潘思娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lunan Pharmaceutical Group Corp
Original Assignee
Lunan Pharmaceutical Group Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010163672.XA external-priority patent/CN113368095A/zh
Priority claimed from CN202010163676.8A external-priority patent/CN113368096A/zh
Application filed by Lunan Pharmaceutical Group Corp filed Critical Lunan Pharmaceutical Group Corp
Publication of CN115175676A publication Critical patent/CN115175676A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21031—Urokinase (3.4.21.31)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种淫羊藿苷元在制备防治出血性疾病药物中的用途，其属于医药领域。淫羊藿苷元能够改善血小板功能障碍，缩短凝血活酶时间，促进凝血，能够用于出血性疾病的防治，尤其是脑梗死出血转化、脑梗死溶栓药物或抗栓药物导致的消化道出血或心肌梗死溶栓药物或抗栓药物出血并发症的治疗。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202180019441.4A 2020-03-10 2021-03-09 淫羊藿苷元的医药用途 Pending CN115175676A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN202010163672X 2020-03-10
CN202010163672.XA CN113368095A (zh) 2020-03-10 2020-03-10 淫羊藿苷元在制备心肌梗死溶栓及抗栓出血并发症防治药物中的用途
CN2020101636715 2020-03-10
CN202010163055X 2020-03-10
CN202010163677 2020-03-10
CN202010163055 2020-03-10
CN2020101636772 2020-03-10
CN2020101636768 2020-03-10
CN202010163676.8A CN113368096A (zh) 2020-03-10 2020-03-10 淫羊藿苷元在制备脑梗死出血转化防治药物中的用途
CN202010163671 2020-03-10
PCT/CN2021/079791 WO2021180087A1 (zh) 2020-03-10 2021-03-09 淫羊藿苷元的医药用途

Publications (1)

Publication Number Publication Date
CN115175676A true CN115175676A (zh) 2022-10-11

Family

ID=77670452

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180019441.4A Pending CN115175676A (zh) 2020-03-10 2021-03-09 淫羊藿苷元的医药用途

Country Status (7)

Country Link
US (1) US20230103858A1 (zh)
EP (1) EP4119139A4 (zh)
JP (1) JP2023518007A (zh)
KR (1) KR20220163389A (zh)
CN (1) CN115175676A (zh)
CA (1) CA3171287A1 (zh)
WO (1) WO2021180087A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104546823A (zh) * 2013-10-21 2015-04-29 鲁南制药集团股份有限公司 淫羊藿苷元在制备治疗或预防血小板减少症药物中的用途
CN104546822A (zh) * 2013-10-21 2015-04-29 鲁南制药集团股份有限公司 淫羊藿苷元的医药用途
WO2016127925A1 (zh) * 2015-02-13 2016-08-18 北京盛诺基医药科技有限公司 一种黄酮化合物的药物组合物及其用途
CN105963293A (zh) * 2016-05-30 2016-09-28 青岛云天生物技术有限公司 一种用于心肌梗死治疗的药物组合物及其应用
CN110357845A (zh) * 2018-03-26 2019-10-22 鲁南制药集团股份有限公司 一种淫羊藿苷元衍生物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399579B1 (en) 2000-08-15 2002-06-04 Hauser, Inc. Compositions comprising icariside I and anhydroicaritin and methods for making the same
CN1194701C (zh) * 2003-06-08 2005-03-30 浙江大学 淫羊藿素或去甲基淫羊藿素在制备雌激素受体调节剂中的应用
CN103690524A (zh) * 2008-08-01 2014-04-02 周亚伟 淫羊藿素在制备防治脑血管疾病药物中的应用
CN101637467A (zh) 2009-08-18 2010-02-03 贾晓斌 淫羊藿苷元或环淫羊藿苷元磷脂复合物及其制备方法
ES2696823T3 (es) * 2013-05-31 2019-01-18 Beijing Shenogen Pharma Group Ltd Uso de icaritina para la preparación de una composición para el tratamiento de cáncer
WO2015058664A1 (zh) * 2013-10-21 2015-04-30 鲁南制药集团股份有限公司 淫羊藿苷元在制备预防或治疗血细胞减少药物中的用途
CA3017366A1 (en) * 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Icariin and icaritin derivatives
CN109369748A (zh) * 2018-10-29 2019-02-22 广东金骏康生物技术有限公司 一种淫羊藿次苷ⅰ类化合物、衍生物、药物组合物及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104546823A (zh) * 2013-10-21 2015-04-29 鲁南制药集团股份有限公司 淫羊藿苷元在制备治疗或预防血小板减少症药物中的用途
CN104546822A (zh) * 2013-10-21 2015-04-29 鲁南制药集团股份有限公司 淫羊藿苷元的医药用途
WO2016127925A1 (zh) * 2015-02-13 2016-08-18 北京盛诺基医药科技有限公司 一种黄酮化合物的药物组合物及其用途
CN105963293A (zh) * 2016-05-30 2016-09-28 青岛云天生物技术有限公司 一种用于心肌梗死治疗的药物组合物及其应用
CN110357845A (zh) * 2018-03-26 2019-10-22 鲁南制药集团股份有限公司 一种淫羊藿苷元衍生物及其制备方法和用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL PHARMACOLOGY: "Anhydroicaritin improves diet-induced obesity and hyperlipidemia and alleviates insulin resistance by suppressing SREBPs activation", BIOCHEMICAL PHARMACOLOGY, vol. 122, 2 November 2016 (2016-11-02), pages 42 - 61, XP029820645, DOI: 10.1016/j.bcp.2016.10.016 *
叶士勇: "淫羊藿苷对血小板活化的影响及其分子机制的研究", 浙江中医杂志, vol. 48, no. 8, 31 August 2013 (2013-08-31), pages 609 - 611 *
李春梅: "淫羊藿苷减轻阿伐他汀诱导的斑马鱼颅内出血", 遵义医学院学报, vol. 37, no. 2, 30 April 2014 (2014-04-30), pages 181 - 187 *
王辰: "淫羊藿苷元微乳制剂对小鼠免疫性血小板 减少性紫癜模型的治疗作用", 中国新药杂志, vol. 26, no. 5, 31 December 2017 (2017-12-31), pages 555 - 561 *

Also Published As

Publication number Publication date
US20230103858A1 (en) 2023-04-06
KR20220163389A (ko) 2022-12-09
WO2021180087A1 (zh) 2021-09-16
CA3171287A1 (en) 2021-09-16
JP2023518007A (ja) 2023-04-27
EP4119139A4 (en) 2024-03-20
EP4119139A1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
JP6294476B2 (ja) 血球減少を予防又は治療するための薬物の製造におけるアンヒドロイカリチンの使用
CN101848711A (zh) 一种药物组合物及其在制备治疗脑血管病药物中的应用
JP2016534074A5 (zh)
CN102068450A (zh) 桃叶珊瑚苷在制备抗血栓形成药物中的应用
CN113925860A (zh) 一种治疗骨关节炎的药物及其应用
CN101279018B (zh) 一种中药脑血疏制剂
JPH0114206B2 (zh)
CN115175676A (zh) 淫羊藿苷元的医药用途
RU2806093C1 (ru) Применение икаритина для получения лекарственных средств
CN112891362B (zh) 一种用于治疗脓毒症的药物组合物及其应用
WO1998024467A1 (fr) Medicaments contre l'hepatite fulminante
CN104814954A (zh) 一种药物制剂及在制备治疗心肌缺血与胃炎药物中的应用
WO2004098623A1 (fr) Injection intraveineuse de saponine de notoginseng et son procede de production
CN111000983A (zh) 一种新的重组人白细胞介素-1受体拮抗剂的药用用途
CN113368098B (zh) 淫羊藿苷元在制备血友病防治药物中的用途
CN101306091B (zh) 荭草和灯盏细辛组合物在制备治疗肾脏疾病药物中的应用
AU749673B2 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
CN110448562A (zh) 羽扇豆酮在制备治疗肾损害药物中的应用
CN110063988A (zh) 一种治疗神经母细胞瘤的药物组合物及其制备方法
CN114306350B (zh) 胆固醇硫酸盐在制备预防脓毒症的药物中的用途
CN113368096A (zh) 淫羊藿苷元在制备脑梗死出血转化防治药物中的用途
CN114191427B (zh) 一种用于抑制血小板活化的药物及其应用
CN113368099B (zh) 淫羊藿苷元在制备血小板功能异常相关疾病防治药物中的用途
CN100450545C (zh) 肌肉生长抑制素在制备抗肿瘤药物中的应用
CN100534458C (zh) 一种治疗中风的药物及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination